Autres langues Lepu Biopharma Co., Ltd.

Actions

2157

CNE100004SM4

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:05 02/07/2024			Varia. 5j.	Varia. 1 janv.
3,44 ^HKD	-2,82%		-12,91%	-18,29%

24/05	Lepu Biopharma présentera trois études lors d'une réunion de la Société américaine d'oncologie clinique ; les actions chutent de 7%.	MT
24/05	Lepu Biopharma Co, Ltd. annonce les résultats de trois essais cliniques présentés à la réunion de l'Asco de 2024 annonce la présentation de trois résultats d'essais cliniques lors de la réunion annuelle de l'Asco en 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7%	24/05
Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting	24/05
Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5%	17/05
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation	11/03
Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer	11/03
Lepu Biopharma Shareholders to Vote Jan. 31 on Contract to Produce Drugs for Lepu Medical Technology	17/01
Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC	28/12
Lepu Biopharma Completes Patient Enrollment for Phase 2B Trial for Nasopharyngeal Cancer Drug	29/12
Lepu Biopharma Renews Procurement Agreement With Lepu Medical Technology	26/12
Lepu Biopharma Gets US FDA's Orphan Drug Designation for Pancreatic Cancer Drug	14/12
Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer	14/12
US FDA Grants Fast Track Designation to Lepu Biopharma's Anti-Cancer Drug	04/12
Lepu Biopharma to Provide Drug Production Services to Lepu Medical Technology	14/11
Lepu Biopharma Divests 15% Stake in Technical Services Provider	29/09/23
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	29/09/23
Lepu Biopharma Co., Ltd.(SEHK:2157) added to S&P Global BMI Index	18/09/23
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Lepu Biopharma Seeks to Extend Validity of Secondary Listing in Shanghai	09/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lepu Biopharma Co., Ltd.

Actions

2157

CNE100004SM4

Autres langues

Filtres